- $2.14bn
- $1.86bn
- $445.76m
- 85
- 33
- 74
- 69
Annual income statement for Veracyte, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 117 | 220 | 297 | 361 | 446 |
| Cost of Revenue | |||||
| Gross Profit | 76 | 145 | 195 | 248 | 298 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 153 | 301 | 338 | 447 | 430 |
| Operating Profit | -35.4 | -81.9 | -41.1 | -85.8 | 16.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -34.9 | -81.6 | -36.4 | -76.6 | 25.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -34.9 | -75.6 | -36.6 | -74.4 | 24.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -34.9 | -75.6 | -36.6 | -74.4 | 24.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -34.9 | -75.6 | -36.6 | -74.4 | 24.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.656 | -0.901 | -0.481 | -0.413 | 0.349 |